carbon tetrachloride

Overview

Carbon tetrachloride (CCl4) is a chlorinated hydrocarbon that has long been used in biomedical research as a hepatotoxic chemical model rather than as a therapeutic agent. In experimental systems, it is commonly administered to induce acute or chronic liver injury, including fibrosis, steatohepatitis-like pathology, and broader oxidative and inflammatory damage. Its utility in research stems from its reproducible ability to trigger hepatocyte injury followed by extracellular matrix deposition, making it a standard tool for studying mechanisms of liver repair, fibrogenesis, and anti-fibrotic interventions.

Biologically, CCl4 is used to model injury pathways involving oxidative stress, inflammatory signaling, activation of hepatic stellate cells, and remodeling of the liver microenvironment. In the recent studies summarized here, CCl4 served as the injury-inducing agent in rat and mouse models of liver fibrosis and metabolic liver disease, enabling evaluation of interventions such as BMSC-Exos, an oral vitamin A-functionalized self-nanoemulsifying drug delivery system (VA-SNEDDS), and Buyanghuanwu decoction, as well as mechanistic studies involving transforming growth factor-beta, PPARα, and fibrosis-associated metabolic pathways.

Focus of Latest Publications

Across the recent publications provided, carbon tetrachloride was used primarily as an experimental inducer of hepatic fibrosis and related liver injury phenotypes.

In the study on melatonin-treated bone marrow mesenchymal stem cell-derived exosomes (BMSC-Exos), CCl4 was used to generate liver fibrosis in male Wistar albino rats. The reported context emphasizes that fibrosis involves replacement of hepatocytes by extracellular matrix proteins and abnormal matrix remodeling. This model allowed investigators to test whether BMSC-Exos could reverse established fibrotic changes, consistent with a regenerative and anti-fibrotic strategy centered on exosome-mediated signaling.

A second fibrosis-focused study evaluated an oral vitamin A-functionalized self-nanoemulsifying drug delivery system (VA-SNEDDS) loaded with MOR in a CCl4-induced fibrotic rat model. The reported findings indicate that treatment significantly attenuated fibrosis by reducing extracellular matrix deposition, hydroxyproline content, and transforming growth factor-β1 (TGF-β1) expression, while also restoring liver function. This places CCl4 as the injury platform for assessing targeted hepatic delivery and anti-fibrotic efficacy.

In another mouse study, Buyanghuanwu decoction (BYHWD) was reported to attenuate hepatic fibrosis in CCl4-induced mice by regulating bile acid metabolism through activation of PPARα. Here, CCl4 again served as the fibrogenic trigger, and the intervention was linked to metabolic regulation rather than only direct suppression of fibrosis markers.

CCl4 was also used in a more complex metabolic liver injury setting. In the study on obesity history and liver macrophage-mediated fibrosis, hepatic fibrosis during weight regain was induced using carbon tetrachloride alongside a second high-fat diet challenge. This design suggests that CCl4 was combined with dietary stress to model more severe or context-dependent fibrotic progression, with macrophage-mediated mechanisms implicated through IGFBP7.

Similarly, in the metabolic dysfunction-associated steatohepatitis work, a new murine model combined an FPC diet with CCl4 for 12 weeks. The publication states that this FPC + CCl4 model induced proper steatohepatitis and more advanced liver fibrosis than other established models. This indicates that CCl4 was used to intensify diet-driven metabolic liver disease into a more fibrotic phenotype suitable for testing interventions such as exogenous 8-hydroxydeoxyguanosine and Rac1-NADPH oxidase signaling.

Although most of the provided contexts involve liver disease, the broader publication set also includes studies on immune and cancer biology in which chemokines such as CCL3, CCL4, and CCL5 were measured in relation to tumor-associated macrophages, checkpoint inhibitor response, and T cell recruitment. These are not CCl4 exposure studies in the chemical sense, but they provide relevant mechanistic context because CCL4 is also the name of a chemokine. In those papers, CCL4 participated in macrophage-centered cytokine circuits, CCR5-linked signaling, and immune infiltration patterns in diseases such as triple-negative breast cancer, non-small-cell lung carcinoma, early-stage melanoma, and urothelial cancer. This should be distinguished from carbon tetrachloride, which is the chemical entity addressed here.

Key Publications

• Jun Melatonin-treated bone marrow mesenchymal stem cell-derived exosomes reverse liver fibrosis induced by CCl4 in male wistar albino rats. (Scientific reports, 2026, PMID 42324293): "Liver fibrosis is defined as the substitution of hepatocytes with extracellular matrix (ECM) proteins, accompanied by abnormalities in matrix remodelling."
• Jun Tumor-educated macrophages promote cytokine-driven lung colonization in triple-negative breast cancer. (Oncoimmunology, 2026, PMID 42319344): "Tumor cells reprogram naïve macrophages into tumor-associated macrophages (TAMs) that secrete CCL3, CCL4, CXCL2, and IL-1β, collectively promoting epithelial-to-mesenchymal transition, migration, transendothelial invasion, and lung colonization."
• Jun Oral self-assembly nanoemulsion drives in vivo hepatic stellate cell-targeting drug delivery in liver fibrosis. (Drug delivery, 2026, PMID 42286842): "In a carbon tetrachloride (CCl4)-induced fibrotic rat model, treatment with MOR-loaded VA-SNEDDS significantly attenuated liver fibrosis by reducing ECM deposition, hydroxyproline content, and transforming growth factor-β1 (TGF-β1) expression while concurrently restoring liver function."
• Jun Buyanghuanwu decoction (BYHWD) attenuates hepatic fibrosis in CCl4-induced mice by regulating bile acid metabolism through activating PPARα. (Journal of ethnopharmacology, 2026, PMID 41796616): "attenuates hepatic fibrosis in CCl4-induced mice by regulating bile acid metabolism through activating PPARα."
• Jun Obesity history exacerbates liver macrophage-mediated fibrosis via IGFBP7. (Biochimica et biophysica acta. Molecular basis of disease, 2026, PMID 42263885): "Hepatic fibrosis during weight regain was induced using carbon tetrachloride (CCl4) alongside a second high-fat diet challenge."
• Jun Targeting XIAP-coordinated PKC signaling resensitizes PD-1-refractory tumors for rechallenge. (Proceedings of the National Academy of Sciences of the United States of America, 2026, PMID 42234523): "...enhancing CD8+ T cell recruitment and effector function through tumor-derived CCL4-CCR5 signaling."
• Jun Systemic Inflammation and Peripheral T Cell Responses Associate With Hepatic Energy Metabolism in Recent-Onset Type 1 Diabetes. (Liver international : official journal of the International Association for the Study of the Liver, 2026, PMID 42130117): "Hepatic Pi was positively associated with circulating MMP10 (r=0.90, p=0.002), with CD4+ T cell responses, particularly CCL3 (r=0.74, p=0.010) and CCL4 (r=0.75, p=0.008), and with CD8+ T cell responses, particularly CCL3 (r=0.86, p=0.014), CCL4 (r=0.96, p<0.001) and TNFSF14 (r=0.89, p=0.007)."
• May Exogenous 8-hydroxydeoxyguanosine prevents liver fibrosis through the regulation of Rac1-NADPH oxidase signaling in a metabolic dysfunction-associated steatohepatitis model. (Free radical research, 2026, PMID 42084856): "The new murine MASH model, the FPC diet with 55% glucose/45% fructose solution plus CCl4 for 12 weeks (FPC + CCl4 model), could induce proper steatohepatitis and more advanced liver fibrosis than the other established models."
• May Conventional type-1 DC density is associated with checkpoint inhibitor response across multiple types of cancer. (The Journal of clinical investigation, 2026, PMID 42065248): "As mechanistically expected, transcripts for the CCL4 and CCL5 chemokines and the growth factor FLT3-L showed associations with cDC1 abundance."
• Apr Mass cytometry uncovers distinct blood myeloid phenotypes linked to clinical responses during gastric cancer chemoimmunotherapy. (Cancer immunology, immunotherapy : CII, 2026, PMID 41915048): "Gene expression analysis showed significantly upregulated CXCL8, CCL3, and CCL4 in FU1 responders."